Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13246331 | 0.85 | POLB (0.58) | POLBMAPTTDP1KDM4EMAPK1 | |
| SCHEMBL10760842 | 0.83 | POLB (0.78) | POLBMAPTTDP1KDM4EMAPK1 | |
| SCHEMBL188449 | 0.83 | HIF1A (0.65) | POLBTDP1ALDH1A1HTTHIF1A | |
| SCHEMBL10533052 | 0.83 | KDM4E (0.52) | POLBMAPTTDP1KDM4EMAPK1 | |
| Hydrochloric Acid SCHEMBL5396629 | 0.82 | HIF1A (0.68) | POLBALDH1A1HTTHIF1A | |
| Hydrochloric Acid SCHEMBL5257349 | 0.82 | HIF1A (0.68) | POLBALDH1A1HTTHIF1A | |
| SCHEMBL6049252 | 0.81 | TDP1 (0.55) | POLBMAPTTDP1KDM4EMAPK1 | |
| SCHEMBL7934862 | 0.80 | MAPT (0.55) | POLBMAPTTDP1KDM4EALDH1A1 | |
| SCHEMBL13952042 | 0.80 | POLB (0.78) | POLBMAPTTDP1KDM4EMAPK1 | |
| SCHEMBL1861868 | 0.78 | ALDH1A1 (0.82) | POLBMAPTTDP1KDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947694-B2 | Substituted pyrazolo[3,4-D]pyrimidines as cell cycle kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-24 | — | — | US | disclosed |
| US-7947694-B2 | Substituted pyrazolo[3,4-D]pyrimidines as cell cycle kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-24 | — | — | US | disclosed |
| US-7749530-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| WO-2010075197-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| US-7692005-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20090208557-A1 | Kinase inhibitors | ALLERGAN, INC. | 2009-08-20 | — | — | US | disclosed |
| EP-1902025-A1 | KINASE INHIBITORS | Allergan, Inc. (US) | 2008-03-26 | — | — | EP | disclosed |
| US-20080039477-A1 | Pyrazolopyrimidines as Cell Cycle Kinase Inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039477-A1 | Pyrazolopyrimidines as Cell Cycle Kinase Inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-14 | — | — | US | disclosed |
| US-20070032478-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2007-02-08 | — | — | US | disclosed |
| WO-2007008895-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039477-A1 | Pyrazolopyrimidines as Cell Cycle Kinase Inhibitors | CDK1, CDK2, CDKN1A | POLB 842/4885MAPT 3998/4885TDP1 613/4885 |
| US-20090208557-A1 | Kinase inhibitors | PTK2, MAP3K6, MAP3K20 | POLB 3520/4885MAPT 1650/4885TDP1 1903/4885 |
| US-20070032478-A1 | Kinase Inhibitors | ABL1, LCK, ERBB2 | POLB 1863/4885MAPT 2433/4885TDP1 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.